4D Molecular Therapeutics FDMT Stock
4D Molecular Therapeutics Price Chart
4D Molecular Therapeutics FDMT Financial and Trading Overview
| 4D Molecular Therapeutics stock price | 26.35 USD |
| Previous Close | 22.09 USD |
| Open | 22.02 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 20.78 - 22.05 USD |
| 52 Week Range | 5.68 - 26.49 USD |
| Volume | 556.85K USD |
| Avg. Volume | 613.18K USD |
| Market Cap | 879.07M USD |
| Beta (5Y Monthly) | 2.488057 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.58 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.86 USD |
FDMT Valuation Measures
| Enterprise Value | 549.95M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.2130175 |
| PEG Ratio (5 yr expected) | 0.65 |
| Price/Sales (ttm) | 398.13165 |
| Price/Book (mrq) | 3.192945 |
| Enterprise Value/Revenue | 249.072 |
| Enterprise Value/EBITDA | -4.967 |
Trading Information
4D Molecular Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.488057 |
| 52-Week Change | 223.57% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 26.49 USD |
| 52 Week Low | 5.68 USD |
| 50-Day Moving Average | 18.4 USD |
| 200-Day Moving Average | 16.65 USD |
FDMT Share Statistics
| Avg. Volume (3 month) | 613.18K USD |
| Avg. Daily Volume (10-Days) | 667.95K USD |
| Shares Outstanding | 41.86M |
| Float | 17.36M |
| Short Ratio | 4.89 |
| % Held by Insiders | 9.76% |
| % Held by Institutions | 86.16% |
| Shares Short | 3.11M |
| Short % of Float | 9.73% |
| Short % of Shares Outstanding | 7.43% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -5151.53% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -24.99% |
| Return on Equity (ttm) | -42.68% |
Income Statement
| Revenue (ttm) | 2.21M USD |
| Revenue Per Share (ttm) | 0.07 USD |
| Quarterly Revenue Growth (yoy) | -75.59% |
| Gross Profit (ttm) | -77124000 USD |
| EBITDA | -110720000 USD |
| Net Income Avi to Common (ttm) | -109838000 USD |
| Diluted EPS (ttm) | -3.21 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 200.45M USD |
| Total Cash Per Share (mrq) | 6.03 USD |
| Total Debt (mrq) | 15.68M USD |
| Total Debt/Equity (mrq) | 7.17 USD |
| Current Ratio (mrq) | 18.358 |
| Book Value Per Share (mrq) | 6.577 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -91041000 USD |
| Levered Free Cash Flow (ttm) | -56366248 USD |
Profile of 4D Molecular Therapeutics
| Country | United States |
| State | CA |
| City | EmeryVille |
| Address | 5858 Horton Street |
| ZIP | 94608 |
| Phone | 510 505 2680 |
| Website | https://www.4dmoleculartherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 137 |
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Q&A For 4D Molecular Therapeutics Stock
What is a current FDMT stock price?
4D Molecular Therapeutics FDMT stock price today per share is 26.35 USD.
How to purchase 4D Molecular Therapeutics stock?
You can buy FDMT shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for 4D Molecular Therapeutics?
The stock symbol or ticker of 4D Molecular Therapeutics is FDMT.
Which industry does the 4D Molecular Therapeutics company belong to?
The 4D Molecular Therapeutics industry is Biotechnology.
How many shares does 4D Molecular Therapeutics have in circulation?
The max supply of 4D Molecular Therapeutics shares is 51.16M.
What is 4D Molecular Therapeutics Price to Earnings Ratio (PE Ratio)?
4D Molecular Therapeutics PE Ratio is now.
What was 4D Molecular Therapeutics earnings per share over the trailing 12 months (TTM)?
4D Molecular Therapeutics EPS is -2.58 USD over the trailing 12 months.
Which sector does the 4D Molecular Therapeutics company belong to?
The 4D Molecular Therapeutics sector is Healthcare.
4D Molecular Therapeutics FDMT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
- {{ link.label }} {{link}}